Promising Data From First-Ever CRISPR Phage Therapy Trial
Locus Biosciences announced that it has completed the world’s first clinical trial using a CRISPR-enhanced bacteriophage therapy in which CRISPR-Cas3 improved the natural ability of the virus to kill the E. coli bacteria behind urinary tract infections. The company decided to take a nuclear approach and to become the first company to combine both mechanisms, […]
